Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2008 Nov;118(11):3582-4.
doi: 10.1172/JCI37553. Epub 2008 Oct 23.

Anticancer therapy: boosting the bang of Bim

Andrea Wahner Hendrickson  1 , Xue Wei Meng, Scott H Kaufmann
Affiliations
Comment

Anticancer therapy: boosting the bang of Bim

Andrea Wahner Hendrickson et al. J Clin Invest. 2008 Nov.

Abstract

Even though activating mutations of B-Raf, a kinase atop the MAPK signaling cascade, reportedly sensitize tumor cells to MEK inhibitors, Raf and MEK inhibitors have exhibited limited clinical activity. In this issue of the JCI, Cragg et al. report that MEK inhibition upregulates the proapoptotic Bcl-2 family member Bim but induces little regression of human melanoma xenografts in mice unless the Bcl-2 antagonist ABT-737 is added (see the related article beginning on page 3651). These findings illustrate the potential benefit of simultaneously inhibiting oncogenic kinases and inhibiting Bcl-2 action in solid tumors.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Overview of signaling pathways affected by MEK inhibitor/ABT-737 combination therapy.
In healthy cells, mitogenic growth factors signaling through the MAPK pathway trigger sequential phosphorylation and activation of MEK and ERK kinases, which in turn leads to stabilization of Mcl-1, activation of Bcl-2, and degradation of Bim, thereby promoting cell survival. In tumors with B-RAF mutations, B-Raf causes pathway activation independent of upstream signaling by either directly activating MEK1/2 or activating c-Raf, depending on the B-Raf variant present. In this issue of the JCI, Cragg et al. show that MEK inhibitors such as U0126, PD098059, and PD325901 upregulate Bim but do not induce regressions of tumors harboring B-RAF mutations (17). The authors also propose that Bcl-2 and Bcl-xL neutralize the increased Bim, thereby diminishing the potential apoptotic effect of the MEK inhibitors. Consistent with this model, the authors show that addition of the Bcl-2/Bcl-xL antagonist ABT-737 enhances the apoptotic effect of MEK inhibition. When Bcl-2 and Bcl-xL are antagonized, the upregulated Bim binds to Mcl-1, causing it to release Bak and/or Bax, leading to cytochrome c release and subsequent apoptosis. Because tumors with B-RAF mutations are dependent on the MAPK pathway rather than the Akt pathway for survival, combining a MEK inhibitor and a Bcl-2/Bcl-xL antagonist appears to be a promising strategy for treating these tumors. c-FLIP, cellular FLICE (caspase 8) inhibitory protein; Grb, growth factor receptor–bound protein 2; GSK, glycogen synthase kinase; mTOR, mammalian target of rapamycin; PDK1, phosphoinositide-dependent kinase 1; PH, pleckstrin homology domain; PIP2, phosphoinositol-4,5-bisphosphate; PIP3, phosphoinositol-3,4,5-trisphosphate; PTEN, phosphatase and tensin homolog; SOS, son of sevenless; XIAP, X-linked inhibitor of apoptosis protein.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wang J.Y., Wilcoxen K.M., Nomoto K., Wu S. Recent advances of MEK inhibitors and their clinical progress. Curr. Top. Med. Chem. 2007;7:1364–1378. doi: 10.2174/156802607781696837. - DOI - PubMed
    1. Tuveson D.A., Weber B.L., Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 2003;4:95–98. doi: 10.1016/S1535-6108(03)00189-2. - DOI - PubMed
    1. Madhunapantula S.V., Robertson G.P. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 2008;68:5–8. doi: 10.1158/0008-5472.CAN-07-2038. - DOI - PubMed
    1. Dancey J.E. Predictive factors for epidermal growth factor receptor inhibitors — the bull’s-eye hits the arrow. Cancer Cell. 2004;5:411–415. doi: 10.1016/S1535-6108(04)00122-9. - DOI - PubMed
    1. Solit D.B., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439:358–362. doi: 10.1038/nature04304. - DOI - PMC - PubMed

Publication types

MeSH terms